Referred to the Committee on Science, Space, and Technology, and in addition to the Committees on Foreign Affairs, Agriculture, Energy and Commerce, and Education and Workforce, f…
Creates a National Biotechnology Initiative led by a National Biotechnology Coordination Office in the Executive Office of the President.
Establishes an interagency committee, a Director, a public website, annual reports, and a 20-year wind-down.
Tasks include coordinating R&D, biological data infrastructure, regulatory streamlining, biosafety/biosecurity, workforce development, commercialization support, and international engagement.
Content is largely administrative and industry-friendly with modest cost, aiding bipartisan support, but procedural issues, oversight concerns, and intercommittee review create uncertainty.
Relative to its intended legislative type, this bill is a well-structured administrative/operational coordination statute that lays out roles, timelines, deliverables, funding for central administration, and recurring oversight. It combines operational creation of an Executive Office entity with reporting and strategy outputs consistent with a cross-cutting initiative.
Progressives stress biosafety, privacy, and transparency concerns.
Progressives stress biosafety, privacy, and transparency concerns.
Generally supportive of federal investment in biotechnology research, workforce development, and public bioliteracy.
Concerned about provisions that ease regulation, possible industry influence, data privacy, and reduced transparency for expert convenings.
Will emphasize stronger safeguards, public-interest research funding, and protections for communities and the environment.
Favors the bill's coordination, national strategy, and emphasis on competitiveness and security, while watching costs and implementation.
Sees value in clearer regulatory pathways but wants accountability, measurable outcomes, and safeguards against duplication or mission creep.
Will seek timely GAO reviews and OMB budget coordination.
Likes focus on competitiveness, commercialization, and national security, but wary of expanding an EOP office and new federal administrative costs.
Concerned about top-down coordination, potential regulatory uncertainty from new pathways, and international obligations.
Prefers private-sector-led innovation and state-level flexibility.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is largely administrative and industry-friendly with modest cost, aiding bipartisan support, but procedural issues, oversight concerns, and intercommittee review create uncertainty.
The bill has not accumulated any surfaced votes yet.
Progressives stress biosafety, privacy, and transparency concerns.
Content is largely administrative and industry-friendly with modest cost, aiding bipartisan support, but procedural issues, oversight conce…
Relative to its intended legislative type, this bill is a well-structured administrative/operational coordination statute that lays out roles, timelines, deliverables, funding for central administration, and recurring o…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.